logo-loader
viewSynairgen PLC

Synairgen surges as it extends SNG001 study to coronavirus patients in home environment

The aim of the extension is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop

Synairgen PLC - Synairgen surges as it extends SNG001 study to coronavirus patients in home environment

Synairgen PLC (LON:SNG) shares surged on Thursday as it said the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment.

The respiratory medicine specialist said the objective is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop.

READ: Synairgen jumps as SNG001 trial on coronavirus patients labelled as an Urgent Public Health study

Meanwhile, the company said the current trial of SNG001 for patients in hospital settings was “progressing well” with more than 75 patients dosed out of the target of 100. Results from this study are expected in June.

The expansion of the trial follows news earlier this month that the trial of SNG001 had been classified as an Urgent Public Health study by the National Institute for Health Research.

Today's news sent the shares up 18.2% to 61.4p in lunchtime trading.

Quick facts: Synairgen PLC

Price: 37.5 GBX

AIM:SNG
Market: AIM
Market Cap: £56.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read